Citations (13)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Jason Shafrin, Jeffrey Sullivan, Jacquelyn W Chou, Michael N Neely, Justin F Doan & J Ross Maclean. (2017) The effect of medication nonadherence on progression-free survival among patients with renal cell carcinoma. Cancer Management and Research 9, pages 731-739.
Read now
Read now
Sumanta K. Pal, Eric Jonasch, James E. Signorovitch, William M. Reichmann, Nanxin Li, Zhimei Liu, Jose Ricardo Perez & Nicholas J. Vogelzang. (2016) Real-world dosing and drug costs with everolimus or axitinib as second targeted therapies for advanced renal cell carcinoma: a retrospective chart review in the US. Journal of Medical Economics 19:5, pages 462-468.
Read now
Read now
Patrick N. Racsa, Tyler R. Whisman & Karen Worley. (2015) Comparing two tyrosine kinase inhibitors for treatment of advanced renal cell carcinoma in Medicare and commercially insured patients. Current Medical Research and Opinion 31:10, pages 1933-1940.
Read now
Read now
Articles from other publishers (10)
Xin-da Song, Yi-nong Tian, Hao Li, Bin Liu, Ai-li Zhang & Yang Hong. (2020) Research progress on advanced renal cell carcinoma. Journal of International Medical Research 48:6, pages 030006052092426.
Crossref
Crossref
Sumanta Pal, Jun Gong, Shivani K. Mhatre, Shih-Wen Lin, Andy Surinach, Sarika Ogale, Rini Vohra, Herschel Wallen & Daniel George. (2019) Real-world treatment patterns and adverse events in metastatic renal cell carcinoma from a large US claims database. BMC Cancer 19:1.
Crossref
Crossref
Qi Li, Xiaoxi Kan, Jie Yin, Lidong Sun, Yajie Wang, Yujie Li, Qing Yang, Hongbin Xiao, Ying Chen, Xiaogang Weng, Weiyan Cai & Xiaoxin Zhu. (2018) Chamaejasmine B Induces the Anergy of Vascular Endothelial Cells to VEGFA Pro-angiogenic Signal by Autophagic Regulation of VEGFR2 in Breast Cancer. Frontiers in Pharmacology 8.
Crossref
Crossref
James E. Frampton. (2017) Pazopanib: a Review in Advanced Renal Cell Carcinoma. Targeted Oncology 12:4, pages 543-554.
Crossref
Crossref
Jens Bedke, Thomas Gauler, Viktor Grünwald, Axel Hegele, Edwin Herrmann, Stefan Hinz, Jan Janssen, Stephan Schmitz, Martin Schostak, Hans Tesch, Stefan Zastrow & Kurt Miller. (2016) Systemic therapy in metastatic renal cell carcinoma. World Journal of Urology 35:2, pages 179-188.
Crossref
Crossref
Gabriella Lupo, Nunzia Caporarello, Melania Olivieri, Martina Cristaldi, Carla Motta, Vincenzo Bramanti, Roberto Avola, Mario Salmeri, Ferdinando Nicoletti & Carmelina D. Anfuso. (2017) Anti-angiogenic Therapy in Cancer: Downsides and New Pivots for Precision Medicine. Frontiers in Pharmacology 07.
Crossref
Crossref
Elizabeth MacLean, Jack Mardekian, Laura A. Cisar, Caroline J. Hoang & James Harnett. (2016) Real-World Treatment Patterns and Costs for Patients with Renal Cell Carcinoma Initiating Treatment with Sunitinib and Pazopanib. Journal of Managed Care & Specialty Pharmacy 22:8, pages 979-990.
Crossref
Crossref
Gordon C Jayson, Robert Kerbel, Lee M Ellis & Adrian L Harris. (2016) Antiangiogenic therapy in oncology: current status and future directions. The Lancet 388:10043, pages 518-529.
Crossref
Crossref
Sumanta K. Pal, James E. Signorovitch, William M. Reichmann, Nanxin Li, Valerie Koo, Zhimei Liu, Jose Ricardo Perez & Nicholas J. Vogelzang. (2016) Real-World Effectiveness of Everolimus Subsequent to Different First Targeted Therapies for the Treatment of Metastatic Renal Cell Carcinoma: Synthesis of Retrospective Chart Reviews. Clinical Genitourinary Cancer 14:2, pages 160-167.e3.
Crossref
Crossref
Lenka Varinska, Peter Gal, Gabriela Mojzisova, Ladislav Mirossay & Jan Mojzis. (2015) Soy and Breast Cancer: Focus on Angiogenesis. International Journal of Molecular Sciences 16:12, pages 11728-11749.
Crossref
Crossref